Co-Diagnostics Expands South Asia Footprint with $13B Market Play

Event summary

  • Co-Diagnostics' Indian JV CoSara expands into Bangladesh, Pakistan, Nepal, and Sri Lanka, adding $13B to regional TAM.
  • Move supports commercialization of PCR Pro® and SARAGENE® products, pending regulatory approvals.
  • CoSara to establish distribution channels, evaluate regulatory pathways, and engage regional partners.
  • Virtual distributor session planned for Q2 2026, with in-person event scheduled for summer 2026.

The big picture

This expansion aligns with Co-Diagnostics' strategy of pre-positioning regional infrastructure ahead of product launches, mirroring similar moves in the U.S. and MENA regions. The $13B TAM underscores South Asia's untapped potential for molecular diagnostics, particularly for tuberculosis, HPV, and respiratory infection testing. Success here could serve as a blueprint for future international growth.

What we're watching

Regulatory Hurdles
The pace at which CoSara secures approvals in Bangladesh, Pakistan, Nepal, and Sri Lanka will dictate commercialization timelines.
Partner Execution
Whether CoSara can effectively establish distribution channels and identify priority customer segments in new markets.
Market Penetration
How Co-Diagnostics' PCR platform competes with existing diagnostics solutions in South Asia's fragmented healthcare landscape.

Related topics

Market Expansion Expansion